Comment from Anonymous
AnonymousSupportIndividual
Summary: The commenter supports the approval of Moderna's mRNA influenza vaccine, arguing that the platform allows for more timely updates and better protection against emerging pathogens. They urge the FDA to proceed with the review based on scientific evidence rather than external interference.
Docket: FDA-2026-N-4162
June 14, 2026
Public Comment for the FDA VRBPAC Meeting on June 18, 2026
To the FDA Vaccines and Related Biological Products Advisory Committee:
I have no conflicts of interest to disclose.
I am in strong support of providing options for enhanced and increased flu vaccination. Moderna’s mRNA vaccine platform allows more timely updates to match circulating strains and to tailor to emerging pathogens such as H5N1 avian flu. Since flu vaccine effectiveness typically ranges between about 30 and 60% in the US, we have substantial room for improvement.
Approval of enhanced vaccine options must be accompanied by effective vaccine campaigns. 2025-2026 flu vaccination rates were just 46% in all adults, and 48% in adults age 65 and older.
FDA’s initial refusal to review Moderna’s flu vaccine appears to be caused by interference efforts by the antivaccine contingency. Vaccine approvals absolutely must be based on scientific evidence and expert review. The US public is expecting you to handle this fairly and honestly, and to proceed toward approval based on science without unnecessary delays.